GLP-1 Medications and Heart Failure: The STEP-HFpEF Breakthrough That's Changing Cardiology

Understanding HFpEF: The Heart Failure Half the World Gets Wrong

Heart failure comes in two major forms. Heart failure with reduced ejection fraction (HFrEF) — the type most people picture — occurs when the heart muscle weakens and can't pump enough blood forward. This type has multiple proven pharmacological treatments including beta-blockers, ACE inhibitors, ARNIs, and SGLT2 inhibitors.

Heart failure with preserved ejection fraction (HFpEF) is different and more complicated. The heart muscle retains normal or near-normal pumping strength (ejection fraction ≥50%), but the ventricle becomes stiff and can't relax and fill properly. Blood backs up into the lungs. Patients experience breathlessness, fatigue, and reduced exercise tolerance — often severe — despite a structurally "normal" pump.

HFpEF accounts for approximately 50% of all heart failure cases and is strongly associated with obesity. In fact, a specific obesity-related HFpEF phenotype — driven by pericardial fat, elevated filling pressures, and metabolic dysfunction — represents a large and growing subset. For years, cardiologists had essentially no pharmacological tools proven to improve outcomes in HFpEF. The disease was managed symptomatically with diuretics. The STEP-HFpEF trials changed that narrative dramatically.

STEP-HFpEF: The Trial That Stunned Cardiologists

STEP-HFpEF enrolled 529 patients with HFpEF (ejection fraction ≥45%), obesity (BMI ≥30), and New York Heart Association class II–IV symptoms — without diabetes. Participants received semaglutide 2.4mg weekly or placebo for 52 weeks. The trial was co-primary endpoint: change in KCCQ-CSS (Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, a validated patient-reported symptom measure) and change in 6-minute walk distance.

Results at 52 weeks:

• KCCQ-CSS improvement: +16.6 points with semaglutide vs. +8.7 points placebo — a treatment difference of 7.8 points, exceeding the 5-point minimum clinically important difference threshold
• 6-minute walk distance: +21.5 meters semaglutide vs. +1.2 meters placebo — a treatment difference of 20.3 meters
• Weight loss: −13.3% semaglutide vs. −2.6% placebo
• CRP (inflammation marker): −43.5% semaglutide vs. −7.3% placebo — signaling strong anti-inflammatory effects independent of weight
• NT-proBNP (heart failure biomarker): Significantly reduced with semaglutide

STEP-HFpEF-DM: The Diabetes Extension

STEP-HFpEF-DM enrolled a parallel cohort of HFpEF patients with type 2 diabetes — a population with even more limited therapeutic options. Results mirrored the non-diabetes trial, with consistent improvements in KCCQ-CSS (+13.7 vs. +6.4 points), 6-minute walk distance, and biomarkers. The consistency across both diabetic and non-diabetic populations strengthened the evidence that the HFpEF benefit is a class effect of GLP-1 receptor agonism, not secondary to diabetes improvement.

The Weight Loss vs. Direct Effect Question

A critical analysis question: are the STEP-HFpEF benefits simply from weight loss, or is there a direct GLP-1 cardiac effect? The researchers addressed this through mediation analysis. While weight loss explained a portion of the benefit, the analysis suggested that a meaningful component of the KCCQ improvement and the CRP reduction was not fully mediated by weight loss — suggesting direct anti-inflammatory and possibly direct cardiac effects of semaglutide.

The CRP reduction is particularly notable: −43.5% is a profound anti-inflammatory effect that substantially exceeds what would be expected from the degree of weight loss alone. GLP-1 receptors are expressed in cardiac tissue, and preclinical research suggests direct cardioprotective effects through multiple pathways including reduced oxidative stress, improved mitochondrial function in cardiomyocytes, and modulation of cardiac fibrosis. The human trial data is consistent with these mechanisms being clinically active.

What This Means for Cardiologists and Their Patients

Across the cardiology community, the STEP-HFpEF data is reshaping referral patterns. Cardiologists managing HFpEF patients with obesity are increasingly considering obesity pharmacotherapy as a primary intervention — not an adjunct — and are referring patients to obesity medicine specialists for GLP-1 therapy initiation.

This represents a significant practice shift. Cardiology has historically viewed weight management as lifestyle medicine — important but peripheral to the pharmacological toolkit. STEP-HFpEF positions semaglutide as a cardiovascular drug with weight-loss properties, rather than a weight-loss drug with cardiovascular properties. That reframing has important implications for how treatment conversations happen and how prescribers think about the risk-benefit calculation.

The 2025 ACC/AHA Heart Failure Guideline update incorporated GLP-1 receptor agonist therapy as a consideration for HFpEF patients with obesity — a formal guideline endorsement that will accelerate adoption across cardiology practices.

Insurance and Access for HFpEF Patients

As with MASH and sleep apnea, HFpEF creates a cardiovascular disease coverage pathway that may be distinct from obesity treatment exclusions in insurance benefit design. Patients with documented HFpEF who are prescribed semaglutide specifically for HFpEF management should explicitly reference the cardiovascular indication in prior authorization requests, not the obesity indication.

Medicare coverage is particularly complex: the HFpEF data has been presented to CMS as supporting coverage under cardiovascular disease management benefit categories rather than the statutory weight-loss exclusion. As of early 2026, coverage decisions vary by Medicare Advantage plan. Traditional Medicare Part D coverage for this indication remains inconsistent. For patients who can't access coverage, compounded semaglutide through telehealth remains the most accessible route. See our full insurance coverage guide.